Malaysians Rush for Anti-Virus Sanitiser, Natshield(TM), after Pharmacies Restock on Concerns of Spread of Deadly Disease
February 06 2020 - 2:00AM
JCN Newswire (English)
KUALA LUMPUR, Feb 6, 2020 - (ACN Newswire) - Amidst growing
concerns of infection by the Wuhan coronavirus, Malaysians queued
up today at local pharmacies to stock up on a handheld
NatShield(TM) sanitizer containing an active ingredient that has
been proven to be effective in combating over 170 deadly pathogens
including previously known coronaviruses.
|
Malaysians queue up to buy
NatShield(TM) Sanitizer to combat coronavirus |
Homegrown healthcare company Holista CollTech ("Holista") said,
since 29 January 2020, it had rushed out the first 5,000 bottles of
the initial order of 60,000 bottles of NatShield(TM) to local
pharmaceutical chains including Big Pharmacy after stocks ran out
earlier in January. The next batch of 15,000 bottles is being
despatched to Malaysian pharmacies this week.
The 20-ml sanitizer retails in Malaysian pharmacies for around
MYR25.00. Each bottle of NatShield(TM) sanitizer contains 5% of
Path-Away(R), a plant-based active ingredient approved by the U.S.
Food and Drug Authority as well as Malaysia's Ministry of Health.
It is also tested at several World Health Organization laboratories
worldwide.
Developed by Global Infections Control Consultants LLC ("GICC LLC")
of South Carolina, U.S.A., Path-Away(R) attacks the cell walls of
the microbes, inhibiting their uptake of amino acids needed for
reproduction. The microbes then clump together and kill themselves
in the process. The alcohol-free Path-Away(R) is not harmful to
humans and is currently sent for testing its effectiveness against
the Wuhan-originated novel coronavirus.
Kuala Lumpur-based Holista, which is listed in Australia, is the
exclusive Path-Away(R) distributor in the ASEAN region. It ships in
the active ingredients which are then bottled under strict
guidelines at several bottling plants in Malaysia. Holista
distributes NatShield(TM) to three chains representing over 3,000
pharmacies across Malaysia.
At a briefing at Big Pharmacy's outlet in Petaling Jaya, Dr Rajen
Manicka, Holista's CEO, said: "The response has been overwhelming.
After stocks ran out on 29th January 2020, we have been working
around the clock to fulfill orders in Malaysia. To date, we have
received confirmed orders for 42,000 bottles of which 5,000 bottles
were sold by the end of last week."
"To cope with the demand, we intend to raise shipments to Malaysia
from the original 60,000 bottles to 145,000 bottles by the end of
February and include both 20-ml and 30-ml sizes. We also plan to
offer a 60-ml family-sized bottle in the coming weeks. Beyond
Malaysia, we have also received many overseas enquiries and we will
update on shipment increases in the next few weeks," he added.
Adding on to this, Lee Meng Chuan, the CEO of Big Pharmacy, said,
"We are doing our best to cope with demand across all 71 outlets.
The health and well-being of our customers are the priority. We
will work closely with Holista in the coming weeks to meet customer
orders."
Holista has agreed to participate in an initiative by the Malaysia
External Trade Development Corporation ("MATRADE"), the national
trade promotion agency, to support victims of the Wuhan
coronavirus. This initiative is known as 'HELP WUHAN'. Holista has
donated RM10,000 as an initial donation and will further donate 2%
of its sales revenue of the NatShield (TM) sanitizers.
Dato' Dr Rajen also announced that Holista will also accelerate the
development of a nasal balm, using the Path-Away(R) active
ingredient, which can reduce risk of infection. Holista intends to
file by March 2020 its own global patent for the nasal balm with a
view to offer a consumer product to the international consumer
market by Q3 2020.
The ingredients of Path-Away(R) are certified as Generally Regarded
As Safe ("GRAS") and approved by the U.S. Food and Drug
Administration (FDA) and exempted by the U.S. Environmental
Protection Agency (EPA). It is listed in the United States
Pharmacopeia (USP) and has undergone successful USP-51 testing as a
disinfectant.
Path-Away(R) is also approved by the Food and Safety Authority and
Environmental Protection Authority of New Zealand. It is approved
for use by Malaysia's Ministry of Health, with special reference to
the H1N1 virus.
Holista is licensed to manufacture and distribute NatShield(TM) in
Southeast Asia.
About Holista CollTech Ltd
Holista CollTech Ltd ("Holista") is a research-driven biotech
company, the result of a merger between Holista Biotech Sdn Bhd and
CollTech Australia Ltd. Headquartered in Perth and with extensive
operations in Malaysia, the company is dedicated to delivering
first-class natural ingredients and wellness products globally.
Holista is a leader in the research of herbs and ingredients for
the making of healthier food.
Listed on the Australian Securities Exchange ("ASX"), Holista
researches, develops, manufactures and markets "health-style"
products to address the unmet and evolving needs of natural
medicine. Holista's suite of ingredients, among other things,
includes low-GI baked products, reduced-sodium salts, low-fat fried
foods and low calories sugar without compromising taste, odour and
mouthfeel. Holista remains the only company to produce sheep
(ovine) collagen using patented extraction methods. For more
information, please refer to http://www.holistaco.com
Contact:
Corporate Affairs & Business Opportunities
Dr Rajen Manicka: rajen.m@holistaco.com
General Enquiries: enquiries@holistaco.com
Media and Investor Relations:
WeR1 Consultants Pte Ltd
E: holista@wer1.net; P: +65 67374844
Source: Holista CollTech Ltd
Copyright 2020 ACN Newswire . All rights reserved. |
Holista Colltech (ASX:HCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Holista Colltech (ASX:HCT)
Historical Stock Chart
From Sep 2023 to Sep 2024